Health Care Technology
Company Overview of Definiens AG
Definiens AG provides biomedical image analysis and data mining software solutions for life sciences, tissue diagnostics, and clinical digital pathology markets. It offers Definiens Tissue Studio, a solution for biomarker and morphological profiling in research and drug discovery on tissue samples, as well as detects regions of interest and distinguishes cell types and cell subtypes within target regions across various tissue slides; and Definiens Developer XD, a solution for scientists and image analysis experts to create and validate automated solutions for a range of biomedical image analysis problems. The company also provides Definiens Image Miner, a solution that integrates data mining...
Founded in 1994
Key Executives for Definiens AG
Founder, Chief Technology Officer and Director
Compensation as of Fiscal Year 2015.
Definiens AG Key Developments
Definiens Increases Global Presence with Opening of Boston Office
Aug 17 15
Definiens AG announced the opening of its second location in the U.S. as a result of the company's growth and expansion in North America. The office, based in Boston, MA, will be managed by Dr. Thomas Nifong, Executive Vice President, Predictive Tests and houses Definiens Tissue Phenomics service team, bioinformatics and customer support for North America. The Boston office will be the primary location for Definiens project managers and services team to execute upon biomarker and companion diagnostic development projects in North America, expanding the company's capacity outside of the Munich headquarters. In addition to the team it currently has in place, the new location will recruit Data Analysts, Biostatisticians, Consultants, and commercially focused employees to meet growing customer demand.
Definiens Releases Biomarker Datafication Services for Oncology Clinical Development
May 29 15
Definiens announced a new suite of Biomarker Datafication Services for oncology clinical development programs. This package of services enables pharmaceutical and biotech companies to gather comprehensive data from their tissue samples which can be used to make critical decisions on drug candidate advancements and assess the potential of companion diagnostics for patient stratification. The Biomarker Datafication Services support data gathering and analysis for researchers working on projects in Exploratory Screening, Pharmacokinetics/Pharmacodynamics, and Companion Diagnostic development. By providing high quality image analysis screening for fast and quantitative measurement, users can receive powerful data output including biomarker expression profiles, biological response to therapy and continuous biomarker readouts, allowing highly advanced decision making and data analysis.
Definiens AG Secures EUR 15 Million Financing for Tissue Phenomics-Based Cancer Diagnostics; Appoints Rainer Strohmenger to the Board of Directors
Jun 23 14
Definiens AG announced that it has closed a round of financing for EUR 15 million. The round was led by Wellington Partners, a leading pan-European venture capital firm. Gilde Healthcare co-led the financing round and was joined by other existing investors Cipio Partners and TVM Capital in the financing. The new funds will allow Definiens to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics. Major investments will be made in executing the company's Tissue Phenomics strategy, enabling partnerships with leading medical centers and pharmaceutical companies to advance the diagnosis and treatment of cancer.
In conjunction with the financing, Dr. Rainer Strohmenger, General Partner and Managing Director for Wellington, will join Definiens' Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 4, 2014